Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | LPL | P06858 | 7/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953691 | 0.89 | CA2 (0.55) | ENPP2CA2CA1LPLLIPG | |
| SCHEMBL248212 | 0.86 | ENPP2 (0.63) | ENPP2CA2CA1LPLLIPG | |
| SCHEMBL1962408 | 0.80 | ENPP2 (0.52) | ENPP2CA2CA1LPLLIPG | |
| SCHEMBL2557686 | 0.80 | ENPP2 (0.52) | ENPP2CA2CA1LPLLIPG | |
| SCHEMBL17394071 | 0.80 | ENPP2 (0.52) | ENPP2CA2CA1LPLLIPG | |
| SCHEMBL2646220 | 0.78 | CA2 (0.53) | ENPP2CA2CA1ALDH1A1CYP3A4 | |
| SCHEMBL680611 | 0.77 | PSIP1 (0.70) | ALDH1A1CYP3A4CYP2C9CYP2C19PSIP1 | |
| SCHEMBL21698566 | 0.77 | LPL (0.47) | ENPP2CA2CA1LPLLIPG | |
| SCHEMBL23088817 | 0.77 | ENPP2 (0.47) | ENPP2CA2CA1LPLLIPG | |
| SCHEMBL7926321 | 0.77 | CA12 (0.62) | ENPP2CA2CA1ALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-3878851-A1 | PROCESS FOR MAKING COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2021-09-15 | — | — | EP | disclosed |
| US-10822331-B2 | Processes for preparing ATR inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-11-03 | — | — | US | disclosed |
| EP-3608316-A1 | DEUTERATED DERIVATIVES OF AN INHIBITOR OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2020-02-12 | — | — | EP | disclosed |
| US-10435397-B2 | — | — | 2019-10-08 | — | — | US | disclosed |
| EP-2940017-B1 | Process for making compounds useful as inhibitors of ATR kinase | VERTEX PHARMA (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20190202818-A1 | PROCESSES FOR PREPARING ATR INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2019-07-04 | — | — | US | disclosed |
| US-10208027-B2 | Processes for preparing ATR inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-02-19 | — | — | US | disclosed |
| US-20130096141-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2013-04-18 | — | — | US | disclosed |
| EP-2427445-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | AstraZeneca AB (SE) | 2012-03-14 | — | — | EP | disclosed |
| WO-2011159657-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2010128324-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096141-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, GPR139 | ENPP2 810/4885CA2 3699/4885CA1 4549/4885 |
| US-10822331-B2 | Processes for preparing ATR inhibitors | ATR, ATRIP, CHEK1 | ENPP2 1231/4885CA2 1969/4885CA1 2900/4885 |
| US-20190202818-A1 | PROCESSES FOR PREPARING ATR INHIBITORS | ATR, ATRIP, CHEK1 | ENPP2 1282/4885CA2 1926/4885CA1 2828/4885 |
| US-10435397-B2 | — | ATR, ATRIP, TBK1 | ENPP2 861/4885CA2 1496/4885CA1 3204/4885 |
| US-10208027-B2 | Processes for preparing ATR inhibitors | ATR, ATRIP, CHEK1 | ENPP2 1282/4885CA2 1926/4885CA1 2828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.